- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01341301
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Human Leukocyte Antigen Partially-Matched Related Donor
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is a phase II study in which patients receive a haploidentical HSCT from a single donor. The period between the donor lymphocyte infusion (DLI) and tolerizing doses of CY has been extended to allow for an increased period of allogeneic response against tumor targets. The outcomes of patients undergoing this extra time period will be compared to historical data to assess efficacy.
Primary Objective:
1) To assess 1 year relapse free survival in patients undergoing hematopoietic stem cell transplant (HSCT) using the Thomas Jefferson University (TJU) 2 step approach with an extra day inserted between the DLI and administration of cyclophosphamide (CY).
Secondary Objectives:
- To assess the consistency and pace of engraftment.
- To assess the pace of T cell and B cell immune recovery.
- To assess regimen related toxicity, (GVHD) graft-versus-host disease incidence and severity, and overall survival in patients undergoing treatment on this protocol. .
- To assess the tolerance of the period of fever, diarrhea, and rash in each arm in an effort to determine whether a longer interval prior to cytoxan changes this side effect qualitatively compared to prior patient groups or concurrent patient groups. N.B. Patients with hematologic malignancies in remission will continue to be transplanted without modification to the original 2-step approach and will serve as a concurrent comparison group.
- To collect leukemia samples prior to transplant and after relapse whenever possible. To assess the overall degree of HLA-class I and class II expression on these paired samples. To test for loss of one or both HLA haplotypes in the relapsed tumor specimens.
- To determine the number of cluster of differentiation 4 (CD4+) cluster of differentiation 25 (CD25+) FOXP3+ regulatory cells post HSCT and to assess whether this is correlated with the development of GVHD after transplant.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Sidney Kimmel Cancer Center at Thomas Jefferson University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Any patient with a hematologic malignancy with residual disease after treatment with 1 or more chemotherapy regimens in whom achievement of remission with additional chemoradiotherapy is felt to be unlikely or who is in 3rd or greater complete remission (CR).
Patients with marrow based diseases in which the marrow biopsy does not meet criteria for active disease (ie <5% blasts in acute leukemia) but who does not have full count recovery will be eligible for treatment on this high risk trial.
- Patients must have at least one related donor who is HLA mismatched in the GVHD direction at two or more HLA loci.
Patients must adequate organ function:
- Left ventricular ejection fraction (LVEF) of >50 %
- Diffusion capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) >50 % of predicted
- Adequate liver function as defined by a serum bilirubin <1.8, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 times upper limit of normal
- Creatinine clearance of > 60 ml/min
- Karnofsky Performance Status of > 80% on the modified KPS tool
- Patients must be willing to use contraception if they have childbearing potential.
- Able to give informed consent
Exclusion Criteria:
- Modified Karnofsky performance status (KPS) of <80%
- > 5 Comorbidity Points on the hematopoietic cell transplantation comorbidity index (HCT-CI) Index
- Untreated class I or II antibodies against donor HLA antigens
- HIV positive
- Active involvement of the central nervous system with malignancy
- Psychiatric disorder that would preclude patients from signing an informed consent
- Pregnancy, or unwillingness to use contraception if they have child bearing potential
- Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder
- Alemtuzumab treatment within 8 weeks of HSCT admission.
- Anti-thymocyte globulin (ATG) level of > 2 ugm/ml
- Patients with active inflammatory processes including Tmax >101 or active tissue inflammation are excluded
- Inability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment plan
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Allogeneic HSCT
CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2. TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0 GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28. |
Studi correlati
Dato IV
Altri nomi:
Dato IV o PO
Altri nomi:
Sottoponiti a DLI
Altri nomi:
Undergo TBI
Altri nomi:
Given IV or PO
Altri nomi:
Undergo allogeneic HSCT
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Lasso di tempo: 1 year after undergoing hematopoietic stem cell transplant
|
To assess relapse free survival in participants undergoing Hematopoietic Stem Cell Transplant (HSCT) using the Thomas Jefferson University 2 step approach with an extra day inserted between the donor lymphocyte infusion (DLI) and administration of cyclophosphamide.
|
1 year after undergoing hematopoietic stem cell transplant
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Pace of T-cell and B-cell Immune Recovery
Lasso di tempo: Assessed up to 1 year
|
Reported descriptively
|
Assessed up to 1 year
|
Regimen Related Toxicities Graded According to the National Cancer Institute (NCI) Common Toxicity Criteria, Version 3.0
Lasso di tempo: Assessed up to 1 year
|
Reported descriptively
|
Assessed up to 1 year
|
Incidence and Severity of GVHD, Graded According to Standard Criteria
Lasso di tempo: Assessed up to 1 year
|
Reported descriptively
|
Assessed up to 1 year
|
Collaboratori e investigatori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Malattie ematologiche
- Neoplasie
- Neoplasie ematologiche
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Inibitori enzimatici
- Agenti antireumatici
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Agenti Antineoplastici, Alchilanti
- Agenti Alchilanti
- Agonisti mieloablativi
- Agenti antibatterici
- Antibiotici, Antineoplastici
- Agenti antitubercolari
- Antibiotici, Antitubercolari
- Inibitori della calcineurina
- Ciclofosfamide
- Tacrolimo
- Acido micofenolico
Altri numeri di identificazione dello studio
- 10D.06
- 2009-41 (Altro identificatore: CCRRC)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Analisi di laboratorio dei biomarcatori
-
ORIOL BESTARDCompletatoTrapianto di rene | Infezione da CMVSpagna, Belgio
-
Progenity, Inc.CompletatoSindrome di Down | Aneuploidia | Sindrome di DiGeorge | Sindrome di Turner | Sindrome di Klinefelter | Delezione cromosomica | Sindrome di Edwards | Sindrome di PatauStati Uniti
-
Vanderbilt University Medical Center4DMedicalCompletato
-
RWTH Aachen UniversitySconosciutoEmorragia subaracnoidea aneurismaticaGermania
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Non ancora reclutamentoInfezioni da HIV | Epatite B
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalReclutamento
-
University of MiamiAttivo, non reclutante
-
Universidad Miguel Hernandez de ElcheInstitut Català de la Salut; Andaluz Health Service; Osakidetza; Servicio Madrileño... e altri collaboratoriCompletatoMalattie professionaliSpagna
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... e altri collaboratoriCompletatoMalattia cardiovascolare | Carenza di vitamina D | Condizioni correlate alla menopausaBrasile
-
RenJi HospitalSconosciutoCarcinoma a cellule squamose dell'esofagoCina